title: Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients.
abstract: BACKGROUND
  Vesicle-associated membrane protein 2 (VAMP2) is a key component of the synaptic vesicle docking/fusion machinery and its mRNA reportedly increases in the frontal cortex of rats following chronic antidepressant and electroconvulsive treatment. VAMP2 is therefore thought to be involved in the mechanism of action of antidepressants and may alter their efficacy. The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine.
  
  
  METHODS
  A total of 106 patients with major depressive disorder were given fluvoxamine (50-200 mg/day) for 8 weeks and assessed for severity of depression using the Semi-Structured Interview Guide of the Hamilton Depressive Scale (SIGH-D; 17 items) at 0 and 8 weeks. We defined a clinical response as more than a 50% reduction in baseline SIGH-D within 8 weeks, and defined clinical remission as a SIGH-D score of less than 7 at 8 weeks. Genotyping was performed by PCR-RFLP.
  
  
  RESULTS
  Analysis of haplotype tagging single nucleotide polymorphisms as well as haplotype analysis did not reveal any significant associations.
  
  
  CONCLUSIONS
  Our results suggest that the VAMP2 gene is unlikely to play a major role in the efficacy of fluvoxamine.
authors.affiliation: Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Saito
authors.forename: Nagahide
authors.initials: N
authors.lastname: Takahashi
authors.forename: Ryoko
authors.initials: R
authors.lastname: Ishihara
authors.forename: Masashi
authors.initials: M
authors.lastname: Ikeda
authors.forename: Tatsuyo
authors.initials: T
authors.lastname: Suzuki
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kitajima
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Yamanouchi
authors.forename: Nakao
authors.initials: N
authors.lastname: Iwata
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Yamada
authors.forename: Keizo
authors.initials: K
authors.lastname: Yoshida
authors.forename: Toshiya
authors.initials: T
authors.lastname: Inada
authors.forename: Norio
authors.initials: N
authors.lastname: Ozaki
mesh_terms: D000328:Adult; D016009:Chi-Square Distribution; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D050988:Vesicle-Associated Membrane Protein 2 / Q000235:genetics*
chemical_list: D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors; D050988:Vesicle-Associated Membrane Protein 2; C494807:VAMP2 protein, human